Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by mikeq113on Sep 09, 2020 2:01pm

141 Views

Post# 31527527

RE:RE:RE:RE:RE:RE:RE:Just a thought

Paul also responded to a question from Leon on behalf of Brian Abrahams at RBC. In his response, he mentioned the following:

"we're confident that within the next couple of months, we'll have a firm plan that we will be very happy to release and dosing patients at the end of this year."

If we want to be quite literal about that, we should expect/hope for news by the end of this month.

Another way we can approach this is to work backwards. If they are committed to "dosing patients at the end of this year", what's the LATEST we could expect to see the trial protocol and endpoints?

Bullboard Posts

Unique Battery Metals opportunity in Quebec